[EFFECT] Kineta, Inc. Common Stock SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

07/02/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 1, 2025

Accession Number:

0001193125-25-152891

Submission Type:

POS AM

CIK:	0001445283
Company Name:	KINETA, INC./DE
File Number:	333-252695

Source: View Original Filing on SEC EDGAR

Kineta, Inc.

NASDAQ:KA

KA Rankings

#9978 Ranked by Market Cap

N/A Ranked by Dividends

KA Latest News

Oct 8, 2024

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Oct 4, 2024

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 2, 2024

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1

Sep 19, 2024

Kineta, Inc Transitioning from Nasdaq to OTC Markets

Aug 19, 2024

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

KA Latest SEC Filings

Jul 2, 2025

[15-12G] Kineta, Inc. Common Stock SEC Filing

Jul 2, 2025

[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Jul 2, 2025

[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Jul 2, 2025

[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Jul 2, 2025

[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

KA Stock Data

Market Cap 7.05M

Float 12.26M

Insiders Ownership 34.89%

Institutions Ownership 6%

Short Percent 0.23%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City MERCER ISLAND